Intratumoral lactate metabolism in barrett's esophagus and adenocarcinoma

Oncotarget

Volumn 8, Issue 14, 2017, Pages 22894-22902

  Huhta, Heikki ^a,b,c   Helminen, Olli ^a,b,c   Palomäki, Sami ^b,c   Kauppila, Joonas H ^a,b,c,d   Saarnio, Juha ^a,b,c   Lehenkari, Petri P ^a,b,c   Karttunen, Tuomo J ^a,b,c  

^a UNIVERSITY OF OULU   (Finland)

^b MEDICAL RESEARCH CENTER OULU   (Finland)

^c OULU UNIVERSITY HOSPITAL   (Finland)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Barrett's esophag; Esophageal adenocarcinoma; MCT1; MCT4; MTCO1

Indexed keywords

CYTOCHROME C OXIDASE; MONOCARBOXYLATE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 4; PROTEIN MTCO1; UNCLASSIFIED DRUG; COTRANSPORTER; CYTOCHROME C OXIDASE SUBUNIT I, HUMAN; LACTIC ACID; MONOCARBOXYLATE TRANSPORT PROTEIN 1; MONOCARBOXYLATE TRANSPORTER; MUSCLE PROTEIN; SLC16A4 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; CYTOPLASM; DISTANT METASTASIS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS DYSPLASIA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METABOLISM; PROTEIN EXPRESSION; ADENOCARCINOMA; ESOPHAGUS TUMOR; FEMALE; MALE; MIDDLE AGED; PATHOLOGY; SURVIVAL ANALYSIS; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; ELECTRON TRANSPORT COMPLEX IV; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; LACTATES; MALE; MIDDLE AGED; MONOCARBOXYLIC ACID TRANSPORTERS; MUSCLE PROTEINS; SURVIVAL ANALYSIS; SYMPORTERS;

EID: 85016997417     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.15284     Document Type: Article

References (34)

1. Bennett C, Vakil N, Bergman J, Harrison R, Odze R, Vieth M, Sanders S, Gay L, Pech O, Longcroft-Wheaton G, Romero Y, Inadomi J, Tack J, et al. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology. 2012; 143:336-346.
2. Coleman HG, Bhat S, Murray LJ, McManus D, Gavin AT, Johnston BT. Increasing incidence of Barrett's oesophagus: a population-based study. Eur J Epidemiol. 2011; 26:739-745.
3. Lopez-Lazaro M. Does hypoxia really control tumor growth? Cell Oncol. 2006; 28:327-329.
4. Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B, Gillies RJ. Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res. 2006; 66:5216-5223.
5. Phelan JJ, MacCarthy F, Feighery R, O'Farrell NJ, Lynam-Lennon N, Doyle B, O'Toole D, Ravi N, Reynolds JV, O'Sullivan J. Differential expression of mitochondrial energy metabolism profiles across the metaplasia-dysplasia-adenocarcinoma disease sequence in Barrett's oesophagus. Cancer Lett. 2014; 354:122-131.
6. Garcia CK, Goldstein JL, Pathak RK, Anderson RG, Brown MS. Molecular characterization of a membrane transporter for lactate, pyruvate, and othermonocarboxylates: implications for the Cori cycle. Cell. 1994; 76:865-873.
7. Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J Clin Invest. 2013; 123:3685-3692.
8. Andersen S, Solstad O, Moi L, Donnem T, Eilertsen M, Nordby Y, Ness N, Richardsen E, Busund LT, Bremnes RM. Organized metabolic crime in prostate cancer: The coexpression of MCT1 in tumor and MCT4 in stroma is an independent prognosticator for biochemical failure. Urol Oncol. 2015; 33:338.317.
9. Curry JM, Tuluc M, Whitaker-Menezes D, Ames JA, Anantharaman A, Butera A, Leiby B, Cognetti DM, Sotgia F, Lisanti MP, Martinez-Outschoorn UE. Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer. Cell cycle (Georgetown, Tex). 2013; 12:1371-1384.
10. Witkiewicz AK, Whitaker-Menezes D, Dasgupta A, Philp NJ, Lin Z, Gandara R, Sneddon S, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Using the 'reverse Warburg effect' to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell cycle (Georgetown, Tex). 2012; 11:1108-1117.
11. Migneco G, Whitaker-Menezes D, Chiavarina B, Castello-Cros R, Pavlides S, Pestell RG, Fatatis A, Flomenberg N, Tsirigos A, Howell A, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling. Cell cycle. 2010; 9:2412-2422.
12. Ullah MS, Davies AJ, Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem. 2006; 281:9030-9037.
13. Dimmer KS, Friedrich B, Lang F, Deitmer JW, Broer S. The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J. 2000; 350:219-227.
14. Pinheiro C, Longatto-Filho A, Simoes K, Jacob CE, Bresciani CJ, Zilberstein B, Cecconello I, Alves VA, Schmitt F, Baltazar F. The prognostic value of CD147/EMMPRIN is associated with monocarboxylate transporter 1 co-expression in gastric cancer. Eur J Cancer. 2009; 45:2418-2424.
15. Mathupala SP, Parajuli P, Sloan AE. Silencing of monocarboxylate transporters via small interfering ribonucleic acid inhibits glycolysis and induces cell death in malignant glioma: an in vitro study. Neurosurgery. 2004; 55:1410-1419; discussion 1419.
16. Pinheiro C, Albergaria A, Paredes J, Sousa B, Dufloth R, Vieira D, Schmitt F, Baltazar F. Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma. Histopathology. 2010; 56:860-867.
17. Koukourakis MI, Giatromanolaki A, Bougioukas G, Sivridis E. Lung cancer: a comparative study of metabolism related protein expression in cancer cells and tumor associated stroma. Cancer Biol Ther. 2007; 6:1476-1479.
18. Chen H, Wang L, Beretov J, Hao J, Xiao W, Li Y. Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression. Clin Exp Metastasis. 2010; 27:557-569.
19. Hao J, Chen H, Madigan MC, Cozzi PJ, Beretov J, Xiao W, Delprado WJ, Russell PJ, Li Y. Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression. Br J Cancer. 2010; 103:1008-1018.
20. Pinheiro C, Longatto-Filho A, Scapulatempo C, Ferreira L, Martins S, Pellerin L, Rodrigues M, Alves VA, Schmitt F, Baltazar F. Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch. 2008; 452:139-146.
21. Pinheiro C, Reis RM, Ricardo S, Longatto-Filho A, Schmitt F, Baltazar F. Expression of monocarboxylate transporters 1, 2, and 4 in human tumours and their association with CD147 and CD44. J Biomed Biotechnol. 2010; 2010:427694.
22. Pertega-Gomes N, Vizcaino JR, Miranda-Goncalves V, Pinheiro C, Silva J, Pereira H, Monteiro P, Henrique RM, Reis RM, Lopes C, Baltazar F. Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC cancer. 2011; 11:312.
23. Dennerlein S, Rehling P. Human mitochondrial COX1 assembly into cytochrome c oxidase at a glance. J Cell Sci. 2015; 128:833-837.
24. Whitaker-Menezes D, Martinez-Outschoorn UE, Lin Z, Ertel A, Flomenberg N, Witkiewicz AK, Birbe RC, Howell A, Pavlides S, Gandara R, Pestell RG, Sotgia F, Philp NJ, et al. Evidence for a stromal-epithelial 'lactate shuttle' in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell cycle (Georgetown, Tex). 2011; 10:1772-1783.
25. Lin CS, Lee HT, Lee MH, Pan SC, Ke CY, Chiu AW, Wei YH. Role of Mitochondrial DNA Copy Number Alteration in Human Renal Cell Carcinoma. Int J Mol Sci. 2016; 17:10.3390/ijms17060814.
26. Jomrich G, Jesch B, Birner P, Schwameis K, Paireder M, Asari R, Schoppmann SF. Stromal expression of carbonic anhydrase IX in esophageal cancer. Clin Transl Oncol. 2014; 16:966-972.
27. Cotter PD, Hill C. Surviving the acid test: responses of gram-positive bacteria to low pH. Microbiol Mol Biol Rev. 2003; 67:53, table of contents.
28. Yang L, Francois F, Pei Z. Molecular pathways: pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus. Clin Cancer Res. 2012; 18:2138-2144.
29. Snider EJ, Freedberg DE, Abrams JA. Potential Role of the Microbiome in Barrett's Esophagus and Esophageal Adenocarcinoma. Dig Dis Sci. 2016; 61:2217-2225.
30. Lochhead P, Chan AT, Nishihara R, Fuchs CS, Beck AH, Giovannucci E, Ogino S. Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Mod Pathol. 2015; 28:14-29.
31. Huhta H, Helminen O, Lehenkari PP, Saarnio J, Karttunen TJ, Kauppila JH. Toll-like receptors 1, 2, 4 and 6 in esophageal epithelium, Barrett's esophagus, dysplasia and adenocarcinoma. Oncotarget. 2016; 7:23658-23667. doi: 10.18632/oncotarget.8151.
32. Helminen O, Huhta H, Lehenkari Petri P, Saarnio J, Karttunen Tuomo J, Kauppila Joonas H. Nucleic acid-sensing Toll-like receptors 3, 7 and 8 in esophageal epithelium, Barrett's esophagus, dysplasia and adenocarcinoma. Oncoimmunology. 2015; 25:5:e1127495.
33. Helminen O, Huhta H, Takala H, Lehenkari PP, Saarnio J, Kauppila JH, Karttunen TJ. Increased Toll-like receptor 5 expression indicates esophageal columnar dysplasia. Virchows Archiv. 2014; 464:11-18.
34. Huhta H, Helminen O, Kauppila JH, Takala H, Metsikko K, Lehenkari P, Saarnio J, Karttunen T. Toll-like receptor 9 expression in the natural history of Barrett mucosa. Virchows Arch. 2015; 467:9-18.